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Abstract
Significance: Maintenance of metabolic homeostasis is critical for cellular and organismal health. Proper
regulation of mitochondrial functions represents a crucial element of overall metabolic homeostasis. Mi-
tochondrial sirtuins (SIRT3, SIRT4, and SIRT5) play pivotal roles in promoting this homeostasis by regu-
lating numerous aspects of mitochondrial metabolism in response to environmental stressors. Recent
Advances: New work has illuminated multiple links between mitochondrial sirtuins and cancer. SIRT5 has
been shown to regulate the recently described post-translational modifications succinyl-lysine, malonyl-
lysine, and glutaryl-lysine. An understanding of these modifications is still in its infancy. Enumeration of
SIRT3 and SIRT5 targets via advanced proteomic techniques promises to dramatically enhance insight into
functions of these proteins. Critical Issues: In this review, we highlight the roles of mitochondrial sirtuins
and their targets in cellular and organismal metabolic homeostasis. Furthermore, we discuss emerging roles
for mitochondrial sirtuins in suppressing and/or promoting tumorigenesis, depending on the cellular and
molecular context. Future Directions: Currently, hundreds of potential SIRT3 and SIRT5 molecular targets
have been identified in proteomic experiments. Future studies will need to validate the major targets of these
enzymes, and elucidate how acetylation and/or acylation modulate their functionality. A great deal of interest
exists in targeting sirtuins pharmacologically; this endeavor will require development of sirtuin-specific
modulators (activators and inhibitors) as potential treatments for cancer and metabolic disease. Antioxid.
Redox Signal. 22, 1060–1077.
Introduction
M itochondria are cytoplasmic organelles that playcentral roles in diverse intracellular processes such as
energy production, metabolism, apoptosis, intracellular sig-
naling, and pathogen responses (158). Mitochondria are re-
sponsible for generating the majority of cellular ATP through
oxidative metabolism by the Krebs cycle, b-oxidation of fatty
acids, and oxidative phosphorylation (OXPHOS). Conse-
quently, mitochondria are the principal source of reactive
oxygen species (ROS) within the cell (92, 163). Under normal
physiological conditions, low levels of ROS can function as
‘‘redox messengers’’ in the regulation of specific signaling
pathways (62), whereas excess ROS beyond the cell’s detox-
ification capacity can damage cellular macromolecules and
promote cell death via the intrinsic apoptotic pathway (28,
146). To neutralize the harmful effects of ROS, cells have
evolved numerous antioxidant systems (123). To meet bio-
energetic demands of the cell, mitochondrial number, config-
uration, and/or activity can change in response to a variety of
physiological conditions (136). Mitochondrial defects, whe-
ther genetic or acquired, are associated with many common
diseases, including diabetes and cancer (162, 169). Therefore,
normal cellular function requires mechanisms to finely regu-
late mitochondrial physiology. In recent years, protein post-
translational modifications (PTMs) such as ADP-ribosylation
and lysine acetylation, succinylation, malonylation, and glu-
tarylation on diverse mitochondrial proteins have emerged as a
novel mechanism of mitochondrial regulation. These modifi-
cations are directly regulated by members of the sirtuin en-
zyme family (2, 34, 91, 121, 156).
Sirtuins are mammalian homologues of the yeast silent in-
formation regulator 2 (Sir2) protein (42). Sirtuins were initially
described as class III histone deacetylases, functionally similar
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to other HDACs. The sirtuin-catalyzed deacetylation reaction
consumes nicotinamide adenine dinucleotide (NAD+ ) as a co-
substrate, and generates the sirtuin feedback inhibitor nico-
tinamide (NAM), 2¢-O-acetyl-ADP-ribose, and a deacetylated
substrate (66). However, certain sirtuins are now known to
possess alternative catalytic functions—for example, deacy-
lase, decrotonylase, desuccinylase, demalonylase, deglutar-
ylase, and ADP-ribosyltransferase activities (Fig. 1)—that
play crucial roles in the regulation of diverse cellular processes
(2, 10, 32, 34, 36, 48, 65, 72, 121, 156).
Owing to their NAD + dependence, fluctuations in NAD +
levels modulate sirtuin catalytic activities. Calorie restriction
(CR), a reduction in calorie intake without malnutrition, is an
intervention that promotes extended healthy lifespan. CR
promotes expression of nicotinamide phosphoribosyl-
transferase (NAMPT), the rate-limiting enzyme of NAD +
biosynthesis, and thus induces increased levels of intracel-
lular NAD + (98). Consistently, increased intracellular
NAD + occur during metabolic stresses such as CR or pro-
longed fasting (19, 20, 105), and are associated with sirtuin
activation in a tissue-specific manner (63, 65). Moreover,
NAMPT expression is linked to the circadian clock, thereby
regulating NAD + levels and sirtuin activity (120). Sirtuins
are widely expressed in normal tissues (99) and play diverse
biological roles such as regulating oxidative stress, DNA
repair, genomic stability, cell survival, apoptosis, metabo-
lism, aging, and longevity (47).
Seven sirtuin members (SIRT1–SIRT7) are encoded in
mammalian genomes. These proteins possess a conserved
NAD+ -binding and catalytic domain, with distinct flanking N-
and C-termini, and differ from one another with regard to
catalytic activities (Fig. 1), subcellular localization (Fig. 2),
protein targets, and biological functions (42, 47). SIRT6 and
SIRT7 are found predominantly in the nucleus, whereas both
SIRT1 and SIRT2 can be nuclear and cytosolic. SIRT3, SIRT4,
and SIRT5 primarily reside in the mitochondrial matrix (25,
47). Here, we focus on SIRT3, SIRT4, and SIRT5: their cata-
lytic activities, protein substrates, major target pathways, and
roles in disease, particularly cancer.
SIRT3: Activity, Expression, and Metabolic Regulation
SIRT3 activity
Among mitochondrial sirtuins, SIRT3 is, by far, the best
characterized, and possesses robust deacetylase activity (93).
SIRT3-deficient mice exhibit elevated mitochondrial protein
acetylation (91). Sol et al. have shown that mouse embryonic
fibroblasts (MEFs) derived from Sirt3 knockout (KO) mice
display increased acetylation of more than 100 lysine sites,
mostly on mitochondrial proteins (147). Using high-resolution
mass spectrometry, two recent studies provided further support
for the role of SIRT3 as a major regulator of the mitochondrial
acetylome, particularly in response to CR or fasting (57, 128).
Interestingly, SIRT3 deacetylase activity exhibits circadian
rhythmicity, attributed to clock-driven oscillation in NAD+
levels in mouse liver (120). Mice with defects in the circadian
clock displayed reduced SIRT3 activity, and increased acety-
lation of multiple mitochondrial enzymes, including well-
known targets of SIRT3. NAD+ supplementation restored
SIRT3 activity and increased oxygen consumption in mice
with defects in the circadian clock (120).
Tan et al. described lysine crotonylation as novel histone
PTM, which is specifically enriched at active gene promoters
and potential enhancers in mammalian genome (155). A very
recent study by Bao et al. reported that SIRT3 possesses
decrotonylase activity, using a similar catalytic mechanism
as for acetyl lysine hydrolysis (10, 36). siRNA-mediated SIRT3
FIG. 1. Catalytic activities of mammalian sirtuins.
SIRT1, SIRT2, and SIRT7 function primarily as deacety-
lases, whereas other mammalian sirtuins catalyze alternative
reactions, in addition to or instead of deacetylation. SIRT4
acts as both a deacetylase and an ADP-ribosyltransferase.
SIRT5 catalyzes desuccinylation, demalonylation, and de-
glutarylation. SIRT6 catalyzes ADP-ribosylation and dea-
cylation, in addition to deacetylation. Only activities shown
to be biologically significant are depicted.
FIG. 2. Subcellular localization of mammalian sirtuins.
SIRT7 is present in the nucleus, whereas SIRT1, SIRT2, and
SIRT6 are both nuclear and cytosolic. SIRT3, SIRT4, and
SIRT5 primarily reside in the mitochondrial matrix; SIRT5
is also found in the cytosol and the nucleus.

















































knockdown (KD) causes accumulation of global histone
crotonylation and enrichment of crotonylation on histone 3
lysine 4 (10). SIRT3 has been reported to interact with
chromatin in U2OS cells, resulting in the repression of ad-
jacent genes (68). Interestingly, SIRT3 KD leads to increased
lysine crotonylation at five of seven genes analyzed in U2OS
cells, along with a significant increase in mRNA levels of
three candidate genes (10). These observations suggest that
SIRT3 might repress the expression of target genes via
modulation of histone lysine crotonylation. This implies the
surprising conclusion that an active fraction of SIRT3 is
present in the nucleus. Indeed, Bao et al. report that a sub-
stantial amount of full-length (unprocessed) SIRT3 is nu-
clear. However, unprocessed human SIRT3 has been
reported to be catalytically inactive, at least with regard to
deacetylation (140). It is conceivable that a fraction of cata-
lytically active SIRT3 is present extra-mitochondrially.
Alternatively, SIRT3 deficiency may modulate cellular me-
tabolism via activity within mitochondria to promote higher
intracellular crotonyl-CoA levels, in turn, leading to in-
creased histone crotonylation. This could occur as a conse-
quence of disordered mitochondrial butyrate or glutaryl
metabolism (155). Clearly, more work is needed to fully
elucidate the role of SIRT3 in modulating crotonyl-lysine
levels, particularly in the extra-mitochondrial compartment.
SIRT3 expression may correlate with human longevity
SIRT3 is expressed abundantly in tissues with high oxida-
tive capacity, such as liver, brain, kidney, skeletal muscle, and
brown adipose tissue, and its expression is increased by CR,
fasting, or exercise (58, 111, 139, 143). Interestingly, increased
expression of SIRT3 may be linked with longevity in humans.
The presence of SNP rs11555236 in linkage disequilibrium
with the putative functional enhancer region of SIRT3, which
is a part of variable number of tandem repeat (VNTR) element
located within a SIRT3 intron (4, 12), has been reported to be
associated with increased longevity in some human popula-
tions (4, 12, 131). SIRT3 expression was higher in peripheral
bloodmononuclear cells from individuals homozygous for this
variant (4). Conversely, SIRT3 expression and activity decline
in response to high-fat feeding (9, 59, 77, 111), in insulin
resistance (174), and in human subjects with the metabolic
syndrome (59). Mice with germline ablation of Sirt3 have no
grossly apparent phenotype under nonstress conditions (91).
Similarly, mice with muscle or liver specific Sirt3 gene dele-
tion are metabolically similar to wild-type (WT) littermates
when fed a normal or high-fat diet (HFD), or under conditions
of fasting, exercise, or cold challenge (37). However, under
stress conditions or with advancing age, SIRT3 plays a crucial
role in attenuating the onset ofmultiple pathologies. In the next
section, we will briefly describe the roles of SIRT3 in regu-
lating mitochondrial metabolism and health (summarized in
Fig. 3). For more details about SIRT3 biology, readers are
referred elsewhere (93).
SIRT3 Regulates Multiple Metabolic Pathways
SIRT3 maintains ATP levels by regulating
mitochondrial electron transport chain function
A major role of SIRT3 is to maintain cellular ATP levels
by promoting mitochondrial electron transport chain (ETC)
activity. Various studies have revealed that SIRT3 deacety-
lates multiple ETC proteins to enhance energy production
and improve ETC efficiency, such as NDUFA9 (complex I),
SDHA (complex II), and the ATP synthase subunit b (com-
plex V) (1, 9, 27, 40, 77, 79, 125). Moreover, the activities of
complexes III and IV are significantly reduced in Sirt3-null
mice under high-fat feeding conditions (77). As a conse-
quence, tissues from SIRT3-deficient mice show decreased
mitochondrial respiration and reduced ATP levels (1).
Role of SIRT3 in acetate metabolism
Acetyl-CoA synthetase 2 (AceCS2), an enzyme catalyzing
the conversion of acetate into acetyl-CoA, was the first
SIRT3 substrate identified (53, 138). Under normal feeding
conditions, AceCS2-deficient mice display no strong phe-
notypes; however, under fasting conditions, they show a 75%
reduction in acetyl-CoA levels, along with a more than 5-fold
increase in plasma acetate levels (134). Indeed, AceCS2
mRNA levels are significantly increased in brown adipose
tissue from fasted WT mice (134) and similar to SIRT3,
AceCS2 is abundantly expressed in tissues such as heart and
skeletal muscle, and its expression is further induced under
FIG. 3. Schematic representation of SIRT3 targets and
downstream functions. SIRT3 deacetylates and activates
multiple targets (green rounded rectangles), which can ei-
ther directly regulate key cellular and physiological pro-
cesses (yellow) or alter the activity (blue ellipse) or
expression levels (blue rectangle) of downstream factors.
Upward and downward red arrows designate promotion or
suppression of particular activity or expression. To see this
illustration in color, the reader is referred to the web version
of this article at www.liebertpub.com/ars

















































ketogenic conditions (43). SIRT3 deacetylates and activates
AceCS2 (53, 138), indicating a role for SIRT3 in acetyl-CoA
generation under fasting conditions in providing the fasting
cells with an alternative source of energy.
SIRT3 promotes fatty acid oxidation
SIRT3 plays a pivotal role in regulating fatty acid b-
oxidation by deacetylation and activation of long-chain-
specific acyl-CoA dehydrogenase (LCAD) (58). Under fast-
ing conditions, SIRT3-deficient mice show decreased fatty
acid b-oxidation, resulting in elevated serum long-chain fatty
acid levels (54, 58). Inefficient fatty acid oxidation may
contribute to the reduced ATP levels of SIRT3-deficient mice
under fasting conditions (1).
As previously mentioned, SIRT3 expression and activity
decline in response to high-fat feeding (9, 59, 77, 111), and
mice lacking SIRT3 show accelerated obesity, insulin resis-
tance, hyperlipidemia, and hepatic steatosis when fed an HFD
over a prolonged period (59). In this context, SIRT3-deficient
mice fed a HFD expressed elevated levels of the lipogenic
enzyme stearoyl-CoA desaturase 1 (SCD1) (59). Increased
SCD1 levels are associated with obesity and type 2 diabetes
(64). Another study demonstrated that SIRT3 suppresses
hepatic lipid accumulation, via AMP-activated kinase
(AMPK)-dependent phosphorylation and inhibition of
acetyl-CoA carboxylase (ACC) (142). ACC is a biotin-
dependent enzyme that plays a crucial role in fatty acid
synthesis by catalyzing the production of malonyl-CoA by
irreversible carboxylation of acetyl-CoA (133).
SIRT3 deacetylates PDC E1a to promote
glucose oxidation
The pyruvate dehydrogenase complex (PDC) catalyzes
oxidative decarboxylation of pyruvate into acetyl-CoA,
which is subsequently used in Krebs cycle to generate ATP
(110, 118). PDC plays a key role in glucose metabolism,
linking glycolysis with the Krebs cycle. Roughly half of all
caloric intake passes through PDC (117). Phosphorylation of
the PDC E1a subunit by pyruvate dehydrogenase kinases
(PDK1–4) inhibits PDC activity, whereas dephosphorylation
by pyruvate dehydrogenase phosphatases (PDP1 and 2) re-
stores its activity (110). Reduced PDC activity and increased
glycolysis are common in cancer cells, as a part of an overall
metabolic reprograming associated with malignancy (179).
Fan et al. found that increased lysine acetylation of PDC E1a
and PDP1 is common in diverse types of human cancer cells
(35). Putative mitochondrial acetyltransferases are poorly
characterized. Acetyl-CoA acetyltransferase 1 (ACAT1) is a
mitochondrial enzyme involved in the final step of isoleucine
catabolism, and it converts 2-methyl-acetoacetyl-CoA into
propionyl-CoA and acetyl-CoA. Fan et al. found that re-
combinant ACAT1 directly acetylates PDC E1a and PDP1
in vitro (35). Further, treatment of PDC E1a and PDP1 with
cell lysates from ACAT1 KD H1299 cells results in their
decreased lysine acetylation and increased activity (35).
Conversely, incubation of recombinant PDC E1a with cell
lysates from SIRT3 KD H1299 leads to their increased
acetylation and decreased activity (35). In EGF-treated can-
cer cells, phosphorylation of PDP1 results in dissociation of
SIRT3 and recruitment of ACAT1, which acetylates PDC
E1a and PDP1. This, in turn, induces dissociation of PDP1
from PDC E1a and recruitment of PDK1, leading to reduced
PDC activity. (35). Indeed, Sirt3 deletion in skeletal muscle
and myoblasts results in increased PDC E1a acetylation, in-
creasing its phosphorylation and decreasing its activity (74).
Decreased PDC activity promotes a switch of skeletal muscle
metabolism from glucose oxidation toward lactate produc-
tion and fatty acid utilization (74). Recently, a study by
Ozden et al. confirmed the role of SIRT3 in directly deace-
tylating PDC E1a (110). A PDC E1a mutant mimicking the
deacetylated state showed increased activity as compared
with an acetylation mimic. Cells expressing an acetylation
mimic showed increased proliferation, colony formation, and
survival on treatment with ionizing radiation, all of which are
characteristics of the transformed state (110).
SIRT3 facilitates ketone body production
SIRT3 also regulates the activity of 3-hydroxy-3-
methylglutaryl CoA synthase 2 (HMGCS2) (144), the en-
zyme that performs the initial step in the conversion of
acetyl-CoA into ketone bodies (acetoacetate and b-
hydroxybutyrate) in the liver. Ketone bodies, in turn, serve
as an important source of energy for tissues such as heart,
skeletal muscle, and brain under fasting conditions. SIRT3-
mediated HMGCS2 deacetylation promotes its activity
and thus facilitates ketone body formation (144). Con-
sequently, Sirt3 KO mice display reduced serum b-
hydroxybutyrate levels during prolonged fasting (144).
SIRT3 regulates the urea cycle via ornithine
transcarbamoylase activation
Using a high-throughput approach combining acetyl-
peptide arrays with metabolomics analysis, Hallows et al.
identified ornithine transcarbamoylase (OTC) as a SIRT3
substrate (54). OTC is an enzyme that catalyzes the second
step of the urea cycle, the key process in the detoxification of
ammonia generated by amino-acid catabolism. SIRT3 di-
rectly deacetylates OTC at lysine 88 and stimulates its ac-
tivity, thus promoting urea cycle function (54). As a
consequence, SIRT3-deficient mice display an inability to
deacetylate and activate mitochondrial OTC, and show urea
cycle functional deficiency in response to CR along with
elevated urinary orotic acid levels (54), a well-known clinical
marker of human OTC deficiency (38).
SIRT3 Promotes Diverse Aspects of Healthy Aging
SIRT3 prevents hearing loss during CR
Age-related hearing loss (AHL), characterized by a decline
of auditory function with increasing age, is associated with
attrition of spiral ganglion neurons and sensory hair cells in
the cochlea of the inner ear (90, 148). Studies have shown that
CR delays the onset of AHL and reduces cochlear pathology
(141, 150) by reducing oxidative stress (150), which plays a
major role in AHL (73, 149). Notably, SIRT3 is required for
the beneficial effect of CR in preserving auditory function.
Hearing function is normal in young SIRT3-deficient mice,
but with age they lose cochlear cells, manifest hearing loss,
even under CR conditions, and display hearing loss (151).
SIRT3 maintains hearing by suppressing oxidative stress
under CR, by deacetylation and activation of isocitrate de-
hydrogenase 2 (IDH2). Activation of IDH2, in turn, increases

















































NADPH levels, used to regenerate reduced glutathione, a key
component of cellular ROS defense (151, 176).
SIRT3 promotes hematopoietic stem cell survival
by reducing oxidative stress
Brown et al. identified a role for SIRT3 in preserving the
functions of hematopoietic stem cells (HSCs) during aging by
lowering ROS levels (15). SIRT3 is dispensable for HSC
function at a young age; however, SIRT3 deficiency results in
a reduced HSC pool size in aged mice. Moreover, in a serial
transplantation experiment, Sirt3 KO results in impaired
HSC self-renewal and reconstitution (15). Indeed, HSCs
from WT aged mice show reduced levels of SIRT3 expres-
sion and activity, contributing to an increase in ROS levels
occurring in aged HSCs. SIRT3 overexpression suppresses
ROS levels via deacetylation and activation of the mito-
chondrial antioxidant enzyme, manganese superoxide dis-
mutase (SOD2), and increases the colony-forming ability of
aged HSCs (15). Moreover, in competitive transplantation
assay, SIRT3 overexpression results in increased functional
reconstitution by HSCs (15). Thus, SIRT3 upregulation re-
juvenates aged HSCs by partially rescuing their functional
defects.
SIRT3 suppresses cardiac hypertrophy
SIRT3 has also emerged as a crucial factor in maintaining
cardiac health (132). Under stress conditions, increased SIRT3
levels in cardiomyocytes are protective against genotoxic and
oxidative stress-mediated cell death (154). Furthermore,
SIRT3-deficient mice show cardiac hypertrophy basally, and
this effect becomes more pronounced in response to hyper-
trophic stimuli (50, 153). Conversely, SIRT3-overexpressing
mice are protected from hypertrophy induction (153). Me-
chanistically, the cardioprotective role of SIRT3 has been as-
cribed to multiple functions of this sirtuin. According to one
proposed mechanism, SIRT3 reduces cellular ROS levels by
deacetylating and activating forkhead box O3a (FoxO3a)
(153), a transcription factor that promotes expression of
antioxidant-encoding genes such as SOD2 and catalase (86,
157). Another study identified a role for SIRT3 in deacety-
lating cyclophilin D, a modulator of the mitochondrial per-
meability transition pore (mPTP), to suppress mPTP opening,
thereby inhibiting induction of cell death in cardiomyocytes
and potentially in other cell types (50, 145). In addition, SIRT3
catalyzes the deacetylation and activation of LKB1, a serine/
threonine kinase that phosphorylates and activates AMPK.
Activated AMPK blocks hypertrophy by a number of mech-
anisms, including promotion of catabolic pathways to upre-
gulate ATP production (122).
SIRT3 regulates mitochondrial fusion
Mitochondrial quality control is crucial for overall cellular
health. In this regard, mitochondria continuously undergo
fusion and fission; a balance between these processes is
necessary to maintain mitochondrial morphology and func-
tion (21). Optic atrophy protein 1 (OPA1), a dynamin-related
GTPase, mediates the fusion of inner mitochondrial mem-
branes (126). A recent study found that activity of OPA1 is
regulated by SIRT3-mediated deacetylation (135). Stress
conditions induce OPA1 hyperacetylation, leading to a
reduction in its GTPase activity. SIRT3 binds to and deace-
tylates OPA1 to restore its activity. Consistently, OPA1
isolated from Sirt3 KO cells displayed reduced GTPase ac-
tivity, and mitochondria isolated from Sirt3 KO hearts
showed disorganized mitochondrial morphology (135), sug-
gesting a role for SIRT3 in maintaining mitochondrial in-
tegrity via OPA1.
SIRT3 plays a role in mitochondrial biogenesis
Maintenance of mitochondrial function and integrity re-
quire the selective degradation of defective mitochondria and
the generation of new mitochondria. While defective mito-
chondria are targeted for degradation by the lysosome for
hydrolytic digestion by a process known as mitophagy, the
process of mitochondrial biogenesis induces mitochondrial
DNA (mtDNA) replication and synthesis of mitochondrial
proteins, resulting in increased mitochondrial number and
mass (14, 106). A major regulator of mitochondrial biogen-
esis is PGC-1a, which, by co-activating NRF-1 and NRF-2,
induces the expression of nuclear encoded mitochondrial
transcription factor A (TFAM) (14, 173). TFAM is an es-
sential protein that binds to mtDNA, regulates mitochondrial
transcription initiation, and participates in mitochondrial
genome replication (17). A study by Kong et al. reported that
PGC-1a promotes expression of the Sirt3 gene in muscle cells
and hepatocytes, mediated by an estrogen-related receptor-
binding element (ERRE) in the Sirt3 promoter (82). Inter-
estingly, activation of Sirt3 gene expression via ERRE is
required for PGC-1a-mediated mitochondrial biogenesis.
Overexpression of PGC-1a results in increased mtDNA copy
number and induces the transcription of cytochrome c oxi-
dase subunits I, II, and VIIa. However, SIRT3 KD impairs
PGC-1a-induced mitochondrial biogenesis and blocks PGC-
1a-induced mitochondria-related gene expression (82). An-
other recent study by Dai et al. showed that treatment of rat
cortical neurons with H2O2 causes oxidative stress-induced
injury and significantly decreases mtDNA content (31).
However, SIRT3 overexpression inhibits H2O2-induced
neuronal damage and increases expression of PGC-1a, NRF-
1, and TFAM, resulting in increased mtDNA content (31).
These findings highlight roles of SIRT3 in regulating mito-
chondrial biogenesis.
SIRT3 regulates the mitochondrial unfolded
protein response
Maintenance of protein homeostasis is essential for cell
function and survival. Accumulation of misfolded and ag-
gregated proteins in the mitochondria induces cellular pro-
teotoxic stress and initiates the mitochondrial unfolded
protein response (UPRmt) (75). The UPRmt activates ex-
pression of nuclear encoded protective genes to reduce pro-
teotoxic stress and to re-establish mitochondrial homeostasis
(56, 75). A recent study by Papa and Germain described a
novel role for SIRT3 in the UPRmt to coordinate both the
antioxidant defenses and mitophagy (112). Proteotoxic stress
leads to increased levels of FoxO3a, SOD2, catalase, and the
autophagy marker LC3B-II (112). Interestingly, proteotoxic
stress also induces SIRT3 expression. siRNA-mediated
SIRT3 inhibition expression significantly attenuates LC3B-II
induction (112). Moreover, SIRT3 inhibition prevents upre-
gulation of SOD2 and FoxO3a and results in a significant

















































increase in mitochondrial O2
- levels after proteotoxic stress.
In addition, loss of SIRT3 leads to a decrease in the mito-
chondrial membrane potential, increases aggregation of mi-
tochondrial proteins, and reduces the viability of cells
undergoing proteotoxic stress (112). These observations in-
dicate that SIRT3 acts as a major coordinator of UPRmt in-
duced by mitochondrial proteotoxic stress.
Roles for SIRT3 in Cancer
SIRT3 functions as a tumor suppressor
The tumor suppressor role of SIRT3 was first identified
with the observations that SIRT3-deficient cells are more
easily transformed than WT controls, and SIRT3-deficient
mice develop mammary tumors with a long latency (51, 79).
SIRT3 expression is reduced in human breast cancer, colon
carcinoma, osteosarcoma, and hepatocellular carcinoma (11,
39, 51, 79, 177, 178). Moreover, deletion of the SIRT3 locus
is present in about 20% of all human cancers, and 40% of
human breast and ovarian cancers, further supporting a
tumor-suppressor role for this protein (39). SIRT3 KD in
human cancer cells resulted in increased tumor size and re-
duced latency in xenografts, whereas SIRT3 overexpression
decreased xenograft tumorigenicity, indicating that SIRT3
continues to retard tumor growth in the context of preformed
cancer cells (11).
As previously noted, SIRT3 functions as a tumor sup-
pressor, in part by suppressing the production of ROS via
deacetylation and activation of antioxidant enzyme SOD2
(124, 159), IDH2 (151), and FoxO3a (153). Increased ROS
levels promote nuclear and mitochondrial genome insta-
bility, and stabilize hypoxia-inducible factor (HIF) 1-
alpha, a part of a protein complex that promotes a shift
toward glycolysis, whose upregulation is associated with
tumor development (11, 39, 79). SIRT3 also plays other
functions that are relevant for tumor suppression. SIRT3
overexpression, by reducing ROS levels, decreases the
expression of the transferrin receptor, TfR1, by inhibiting
iron regulatory protein 1 (IRP1), thereby suppressing the
proliferation of pancreatic cancer cells (70). IRP1, which
serves as an ROS sensor (100), displays reduced binding to
the iron response element (IRE) in SIRT3 overexpressing
cells (70). IRE is found in the 5¢ untranslated regions of
mRNAs whose protein products are associated with iron
metabolism. Furthermore, SIRT3 may also be involved in
tumor suppression by modulating the activity of extra-
mitochondrial factors. In this regard, Inuzuka et al. found
that SIRT3 deacetylates the proto-oncoprotein S-phase
kinase-associated protein 2 (Skp2) (67), which is over-
expressed in multiple types of cancer and functions as an
E3 ubiquitin ligase to target numerous tumor suppres-
sors for proteasome-mediated degradation (41). SIRT3-
mediated deacetylation leads to Skp2 nuclear import,
thereby preventing its targeting of E-cadherin (67). Re-
duced E-cadherin expression occurs in many cancer types,
and is a characteristic of epithelial-mesenchymal transition
and cancer metastasis (160). Overall, these studies indicate
that SIRT3 functions as a tumor suppressor by increasing
mitochondrial respiration, repressing ROS production,
promoting nuclear and mtDNA integrity, destabilizing
HIF1-alpha, decreasing TfR1 expression, and promoting
nuclear import of Skp2.
Potential role of SIRT3 in tumor promotion
As with other sirtuins (179), there are reports of tumor-
promoting roles for SIRT3. SIRT3 is overexpressed in many
oral squamous cell carcinomas (OSCCs) relative to normal
oral mucosa, and SIRT3 depletion in these cells impairs their
growth and proliferation, and sensitizes them to genotoxic
therapy (5). However, another study reported that despite
increased expression of SIRT3 in OSCC, its catalytic activity
is significantly reduced (22). Further, it has been found that
23.8% of OSCC patients analyzed carried a germline point
mutation in SIRT3, resulting in substitution of a valine resi-
due with isoleucine at position 208 in the SIRT3 catalytic
domain (22). Recombinant SIRT3 with this V208I mutation
displayed reduced catalytic efficiency (22). Consistent with
the notion that SIRT3 can play an oncogenic function, a re-
cent study reported the presence of an extra copy of the SIRT3
locus in a family with Li-Fraumeni Syndrome (8), an in-
herited condition characterized by an increased risk of de-
veloping diverse cancer types. Consistently, Ashraf et al.
reported that increased SIRT3 expression was associated
with human lymph node-positive breast cancer (7). In context
of these observations, ectopic expression of SIRT3 rescued
p53-induced growth arrest in human bladder tumor-derived
Ej-p53 cells (87). These opposing roles of SIRT3, as both a
tumor suppressor and an oncogene, are context- and cell-type
specific.
SIRT4-Regulated Processes:
Targets and Physiological Implications
Although SIRT4 possesses a conserved sirtuin deacetylase
domain (42), initial reports did not identify any deacetylase
activity of this sirtuin (2, 52, 107). Recently, however, SIRT4 has
been reported to possess specific deacetylase activity toward at
least one particular substrate (see subsequent section on SIRT4
and fatty acid metabolism) (84). SIRT4 also exhibits strong
ADP-ribosyltransferase activity (2, 52). In the next sections, we
describe the effect of SIRT4-mediated regulation on various
target substrates (Fig. 4) and their physiological functions.
SIRT4 suppresses glutamate dehydrogenase activity
The first target of SIRT4 identified was glutamate dehy-
drogenase (GDH), a mitochondrial enzyme that catalyzes the
second step in glutamine catabolism. Glutamine is initially
hydrolyzed by glutamate synthase (GLS) to glutamate, which
is then subsequently converted to a Krebs cycle intermediate,
a-ketoglutarate, by the action of GDH (95). SIRT4 interacts
with GDH in pancreatic b-cells and ADP-ribosylates GDH to
repress its activity (52). Pancreatic islets isolated from Sirt4
KO mice show increased GDH activity compared with con-
trols. The SIRT4-mediated decrease in GDH activity results
in the repression of amino-acid-stimulated insulin secretion
(AASIS) in pancreatic b-cells and, thus, Sirt4 KO mice show
elevated circulating insulin levels (52). These observations
suggest an inhibitory role of SIRT4 in glutamine metabolism
by repressing the activity of GDH.
SIRT4 inhibits fatty acid metabolism
SIRT4 deacetylates and inhibits malonyl-CoA decarbox-
ylase. Malonyl-CoA decarboxylase (MCD) is an enzyme
that catalyzes the generation of acetyl-CoA from malonyl-

















































CoA. Malonyl-CoA, in turn, allosterically inhibits the ac-
tivity of carnitine palmitoyltransferase 1 (CPT1), the enzyme
that catalyzes mitochondrial uptake of fatty acids for b-
oxidation (133). Under nutrient-rich conditions, SIRT4 dea-
cetylates MCD, thereby repressing its activity (84). SIRT4
overexpression in myocytes and adipocytes resulted in re-
duced MCD activity, whereas muscles and white adipose
tissues from Sirt4 KO mice showed elevated MCD activity
and a reduction in malonyl-CoA levels (84). As a conse-
quence, Sirt4KOmice showed increased fatty acid oxidation,
associated with increased exercise capacity and resistance to
diet-induced obesity (84). However, SIRT4-deficient mice
did not show improved insulin sensitivity commensurate with
their relative leanness.
SIRT4 inhibits b-oxidation gene expression by repressing
PPARa activity. Peroxisome-activated receptor a (PPARa)
is a ligand-activated transcription factor that promotes the
expression of genes involved in fatty acid catabolism (78,
85). Nasrin et al. reported that SIRT4 KD in mouse primary
hepatocytes andmyotubes resulted in increased expression of
genes encoding fatty acid metabolism enzymes, along with
elevated SIRT1 expression (104). Consequently, a significant
increase in fatty acid oxidation was observed upon SIRT4KD
in primary hepatocytes, which was found to be SIRT1 de-
pendent, as SIRT1/SIRT4 double KD hepatocytes showed a
blunted increase in fatty acid oxidation (104). Recently,
SIRT4 overexpression has been shown to repress PPARa
transcriptional activity, resulting in suppression of fatty acid
catabolism gene expression, and, hence, reduced fatty acid
oxidation (83). Conversely, PPARa target gene expression
levels were remarkably elevated in Sirt4KO livers (83). Sirt4
deletion resulted in increased NAD + levels, leading to in-
creased activity of SIRT1. Interestingly, SIRT1 has been
shown to activate PPARa, and this activation was repressed
by SIRT4 overexpression (83). Collectively, both studies
identify SIRT4 as a suppressor of fatty acid oxidation by
inhibiting SIRT1-mediated activation of PPARa.
SIRT4 negatively regulates AMPK activity to suppress
fatty acid oxidation. AMPK plays a key role in promoting
fatty acid oxidation, by phosphorylating and inhibiting ACC.
As previously mentioned, ACC catalyzes the production of
malonyl-CoA from acetyl-CoA. Thus, AMPK-driven ACC
phosphorylation reduces malonyl-CoA levels, resulting in
increased CPT1-mediated mitochondrial fatty acid uptake (3,
133, 172). A recent study showed that during fasting, in-
creased SIRT4 levels inhibit AMPK activity and suppress
fatty acid oxidation (61). AMPK also activates PGC-1a, a
transcriptional co-activator of fatty acid oxidation genes
(164). Consistent with these reports, livers from Sirt4 KO
mice showed elevated levels of active AMPK, resulting in
increased phosphorylated ACC and PGC1-a induction (61).
ANT2 is a mitochondrial protein associated with the inner
mitochondrial membrane that catalyzes the exchange of ATP
generated in the mitochondria with cytosolic ADP (119).
ANT2 KD in SIRT4-overexpressing cells rescues decreased
AMPK activity, indicating that ANT2 plays a crucial role in
SIRT4-dependent AMPK regulation (61). Altogether, SIRT4
suppresses fatty acid oxidation by modulating the activity of
MCD, PPARa, and AMPK.
Other targets of SIRT4
Caspases are a family of cysteine proteases that play key
roles in apoptosis. SIRT4 overexpression decreases the activ-
ities of caspases 3 and 7 under hypoxic conditions, and reduces
induction of caspases 3 and 9 by hypoxia (89). Consequently,
SIRT4 protects H9c2 cardiomyoblast cells against hypoxia-
induced apoptosis (89). More recently, SIRT4 has been shown
to inhibit the activity of NF-jB by inhibiting IkBa degradation
(23). NF-jB is a transcription factor that plays a key role in
inflammatory responses, and transcriptionally regulates the
expression of surface adhesion molecules, such as VCAM-1
and E-selectin. Treatment of human pulmonary microvascular
endothelial cells (HPMECs) with cigarette smoke extract
(CSE) strongly induces expression of VCAM-1 and E-selectin
(23). However, overexpression of SIRT4 in HPMECs inhibits
the CSE-induced expression of these surface adhesion mole-
cules and mononuclear cell adhesion (23). Tissues and cells
FIG. 4. Overview of SIRT4 target substrates and cel-
lular functions. SIRT4 directly (red rounded rectangles) or
indirectly (green ellipses) modulates the activity of various
target substrates, which either regulate aspects of fatty acid
metabolism (yellow rectangles) or play crucial roles in other
cellular processes (blue rounded rectangles). Upward and
downward red arrows indicate the promotion or suppression
of a particular activity, gene expression, or physiological
activity. To see this illustration in color, the reader is referred
to the web version of this article at www.liebertpub.com/ars

















































from Sirt4 KO mice show reduced ATP levels, whereas
overexpression of SIRT4 increases ATP content (61). The
interaction of SIRT4 with ANT2 is essential for maintaining
ATP homeostasis (61). However, there are no reports showing
that SIRT4 biochemically modifies ANT2.
SIRT4 Acts as a Tumor Suppressor via Repression
of Glutamine Metabolism
SIRT4mRNA levels are reduced in several human cancers
(13, 26, 45, 71, 170), and reduced SIRT4 mRNA levels
correlate with inferior survival in patients with lung tumors
(71). Recent studies confirmed that SIRT4 indeed acts as a
tumor suppressor, by repressing glutamine metabolism and
promoting genomic stability (30, 69, 71). Glutamine is a key
amino acid required for diverse intracellular processes such
as macromolecular synthesis, redox homeostasis, oxidative
metabolism, and many others (95). Although most mamma-
lian cells can synthesize glutamine, under conditions of rapid
cell proliferation, such as cancer, a steady extracellular
source of glutamine becomes essential. Glutamine serves as
an anaplerotic substrate by replenishing the Krebs cycle via
a-ketoglutarate, a product of glutamine catabolism. Con-
sistently, many cancer cells are ‘‘glutamine addicted,’’ and
require exogenous glutamine to support survival and prolif-
eration (95). For example, cell cycle progression in HeLa
cells is absolutely dependent on glutamine (29). Jeong et al.
showed that genotoxic stress, which arrests cell cycle pro-
gression to allow DNA damage repair, induces SIRT4 ex-
pression, which, in turn, represses mitochondrial glutamine
metabolism (71). Sirt4 KO MEFs show increased entry of
glutamine-derived metabolites into the Krebs cycle, and are
unable to repress cellular glutamine uptake in response to
DNA damage (71). Moreover, these cells display an
increased proliferation rate, a phenotype abrogated by inhibi-
tors of glutamine metabolism, highlighting the glutamine-
dependent proliferation of these cells (71). Consistently, HeLa
cells, which use glutamine as a major energy source, show
growth inhibition in response to SIRT4 overexpression (71).
Moreover, SIRT4 deficiency is associated with larger tumor
formation in a nude mice allograft model, and two indepen-
dently derived strains of Sirt4 KO mice displayed increased
incidence of spontaneous lung tumors (71).
The tumor-suppressor activity of SIRT4 was further
evaluated in the context of Myc-driven human Burkitt lym-
phoma cells (69). c-Myc is a transcription factor that upre-
gulates glutaminase expression, by reducing the expression
of inhibitory microRNAs targeting this mRNA (95). Myc-
driven cancers typically show marked glutamine dependence
(44, 168). Overexpression of SIRT4 reduces glutamine uti-
lization in Burkitt lymphoma cells, inhibits their prolifera-
tion, and sensitizes them to glucose depletion (69). Moreover,
loss of SIRT4 in a mouse Burkitt lymphoma model increases
lymphomagenesis and mortality. Malignant B cells derived
from these mice display increased glutamine uptake and
GDH activity (69).
Csibi et al. showed that a mechanistic target of rapamycin
complex 1 (mTORC1) negatively regulates SIRT4 expres-
sion by promoting proteasome-mediated degradation of the
SIRT4 transcriptional regulator CREB2 (30). Tuberous
sclerosis 2 (TSC2) is a negative regulator of mTORC1; thus,
Tsc2 KO MEFs show increased mTORC1 activation.
Inhibition of mTORC1 activity by rapamycin results in in-
creased SIRT4 expression and reduced GDH activity in Tsc2
KO cells (30). Consistently, SIRT4 overexpression inhibits
transformation and proliferation of Tsc2 KO MEFs in vitro,
and delays tumor development in xenograft models (30).
SIRT5 Regulates Newly Described PTMs
SIRT5 is phylogenetically most closely related to pro-
karyotic (so-called class III) sirtuins (42). SIRT5 is broadly
expressed with the highest expression levels in brain, heart,
liver, kidney, muscles, and testis (99, 102). SIRT5 is pre-
dominantly mitochondrial (33, 99, 102, 137); however,
several reports have revealed the existence of functional
extra-mitochondrial SIRT5 (46, 96, 116). In this regard, Park
et al. reported that a significant amount of SIRT5 is present in
the cytosol in mouse hepatocytes and human 293T cells, and
that a number of cytosolic and nuclear proteins, in addition to
many mitochondrial proteins, were hypersuccinylated in the
absence of SIRT5 (116). To date, no strong phenotype or
major metabolic abnormality has been described in Sirt5 KO
mice (91, 101, 175). Thus, SIRT5 seems to be largely dis-
pensable for gross metabolic homeostasis under basal, un-
stressed conditions, which is true of most sirtuins except
SIRT1 and SIRT6. SIRT5 overexpression was reported to
enhance ATP synthesis and oxygen consumption in HepG2
cells, whereas SIRT5 KD had no effect in this context (16).
Conversely, SIRT5 KD human cells and mitochondria iso-
lated from SIRT5-deficient mouse livers showed increased
respiration in the presence of succinate and pyruvate, indi-
cating that SIRT5 inhibits mitochondrial respiration under
some conditions (116).
SIRT5 and Protein Deacylation
Based on homology to other sirtuins, SIRT5 was originally
annotated as a deacetylase (42). However, recently SIRT5
has been shown to preferentially deacylate negatively
charged modifications: malonylation, succinylation, and
glutarylation (34, 116, 121, 127, 156). Du et al. showed that
SIRT5 possesses minimal deacetylase activity compared
with SIRT1 and SIRT3 (34); however, the catalytic efficiency
of SIRT5 for demalonylation and desuccinylation was much
higher than for deacetylation (34, 121). Protein lysates from
SIRT5-deficient livers showed increased lysine malonylation
and lysine succinylation, with little impact on lysine acety-
lation (121). Du et al. described the presence of an arginine
residue (Arg105) and tyrosine residue (Tyr102) in the acyl-
binding pocket of SIRT5, which are conserved in most class
III sirtuins (34). The presence of arginine and tyrosine resi-
dues in the catalytic pocket of SIRT5 is likely responsible for
their preference for negatively charged acyl groups.
Via mass spectrometry approaches, two independent
studies have identified multiple SIRT5 succinylated targets in
mouse liver mitochondria (127), and globally in MEFs and
liver tissues (116). Among the quantifiable sites identified by
Park et al., more than 90% showed hypersuccinylation in
Sirt5 KO cells, strongly suggesting that SIRT5 is a major
regulator of lysine succinylation in mammals (116). Simi-
larly, Rardin et al. reported that SIRT5 deficiency resulted in
hypersuccinylation of 32% sites in 56% of mitochondrial
proteins overall (127). The preference of SIRT5 for nega-
tively charged acyl groups was further corroborated by

















































another recent study (156). Tan et al. identified and validated
lysine glutarylation as an evolutionary conserved post-
translational modification; similar to lysine succinylation,
this modification was also regulated by SIRT5 (156). Pro-
teomic screening of liver extracts from Sirt5 KO mice re-
vealed hyperglutarylation of 683 lysine sites on 191 proteins;
more than three quarters of these proteins were found to be
mitochondrial (156). These studies emphasize the major
cellular role of SIRT5 in removing negatively charged lysine
modifications, primarily within the mitochondrial matrix.
Although many metabolic enzymes have been identified as
malonylated or succinylated, the significance of these PTMs
is still unclear. It has been proposed that protein acylation
results from the nonenzymatic lysine modification (167), due
to accumulation of intrinsically reactive carbon metabolites,
which can negatively impact protein function and, hence,
disrupt cellular homeostasis (166). Therefore, by removing
these lysine PTMs, sirtuins may contribute to maintaining the
quality of the proteome, especially in mitochondria.
Metabolic Targets of SIRT5
Similar to other sirtuins, SIRT5 targets a number of protein
substrates (Fig. 5) implicated in diverse metabolic pathways.
Cytochrome c, a mitochondrial protein with central roles in
oxidative metabolism and apoptosis, was the first reported
target of SIRT5 (137). However, no in vivo evidence indi-
cates a role for SIRT5 in regulating functions of this protein.
Carbamoyl phosphate synthetase 1 (CPS1) is the enzyme
catalyzing the initial step of the urea cycle for ammonia
detoxification and disposal (55, 97). Deacetylation (102),
desuccinylation (34), and deglutarylation (156) of CPS1 by
SIRT5 result in its increased enzymatic activity. Sirt5-null
mice display lower CPS1 activity (34, 102) and have reduced
capacity to detoxify ammonia. During conditions of high
amino-acid catabolism (fasting, CR, or a high protein diet),
SIRT5-deficient mice showed elevated blood ammonia levels
(102). These findings were further complemented by another
study, which revealed increased expression of Sirt5mRNA in
the livers of WT mice during fasting, and, in addition, in-
creased CPS1 activity in the livers of SIRT5-overexpressing
transgenic mice (108). Analysis of mitochondrial proteins in
the livers of SIRT5-overexpressing transgenic mice identi-
fied urate oxidase as another target of SIRT5 (103). Urate
oxidase catalyzes the conversion of urate to allantoin, the last
step of purine catabolism in most mammals (but not humans)
(6). In the livers of SIRT5-overexpressing transgenic mice,
urate oxidase showed decreased acetylation and increased
activity (103).
In the context of ROSmanagement, it was recently shown
that SIRT5 binds to, desuccinylates, and activates Cu/Zn
superoxide dismutase (SOD1). SOD1 is a key cellular an-
tioxidant enzyme, and SOD1-mediated ROS detoxification
is significantly increased when SOD1 is co-overexpressed
with SIRT5 (88). A number of observations potentially
implicate SOD1 in tumorigenesis (114). For example, in-
creased SOD1 expression was found in a panel of breast
cancer cell lines (113); overexpression of SOD1 promotes
growth of lung cancer cells (152); and inhibition of SOD1
induces cell death in the lung carcinoma cell line A549 (49).
Mutation of the SOD1 succinylation site inhibited the
growth of lung cancer cells (88), suggesting a role for
SIRT5-mediated SOD1 desuccinylation and activation in
promoting tumorigenesis.
In their global analysis of lysine succinylation, Park et al.
reported widespread succinylation in diverse mitochondrial
metabolic enzymes (116). Among a large number of putative
SIRT5 targets, they further analyzed the role of SIRT5 in
regulating PDC E1a and succinate dehydrogenase (SDH), an
enzyme that catalyzes the oxidation of succinate to fumarate.
SIRT5 robustly desuccinylated PDC E1a in vitro and re-
pressed its activity. Consequently, SIRT5 KD resulted in
elevated PDC E1a activity, along with a substantial increase
in SDH activity and elevated cellular respiration (116).
Rardin et al. showed hypersuccinylation of HMGCS2 in the
absence of SIRT5 (127). HMGCS2 is the rate-limiting en-
zyme of ketone body synthesis, and hypersuccinylation de-
creases its activity. Consequently, there is a mild defect in
ketone body formation during fasting in SIRT5-deficient
animals (127). Loss of SIRT5 also leads to hypersuccinyla-
tion of proteins involved in fatty acid b-oxidation; liver and
skeletal muscle from Sirt5 KO mice show modest accumu-
lation of medium- and long-chain acylcarnitines (127).
Overall, SIRT5 target a number of protein substrates in-
volved in glucose oxidation, ketone body formation, fatty
acid oxidation, ammonia detoxification, and ROS manage-
ment. One way to rationalize the functions of SIRT5 may be
that this protein suppresses glucose oxidation while facili-
tating use of alternative energy sources, such as fatty acids,
ketone bodies, and amino acids. These conditions occur
during fasting and CR. However, no role for SIRT5 in CR has
been directly identified as yet.
FIG. 5. Major targets regulated by SIRT5. SIRT5
deacetylates, desuccinylates, demalonylates, and/or deglu-
tarylates multiple metabolic enzymes to activate (blue el-
lipses) or inhibit (green ellipses), either increasing (yellow
rounded rectangle with upward red arrow) or decreasing
(yellow rounded rectangles with downward red arrow) the
levels/activity of particular compound/cellular activity. To
see this illustration in color, the reader is referred to the web
version of this article at www.liebertpub.com/ars


















































Until recently, no reports assessed roles for SIRT5 in any
type of malignancy. A recent analysis of human high-grade
serous ovarian carcinomas found that the region encom-
passing the SIRT5 locus was amplified in 30% of these tumors
(18). Altered activities of SIRT5 targets, PDC and SDH, are
implicated in neoplasia and cancer cell metabolic repro-
gramming. As previously noted, PDC activity is frequently
suppressed in tumor cells, in part via reversible phosphory-
lation (60, 76, 80, 81, 109, 115, 129, 130). It is possible that
SIRT5 contributes to metabolic reprogramming in cancer
cells, potentially by participating in PDC inhibition. Very
recently, Lu et al. showed that SIRT5 is overexpressed in
advanced non-small cell lung cancer (NSCLC), and that
SIRT5 KD repressed the growth rate of NSCLC cell lines
(94). SIRT5 KD in these cells increased their susceptibility to
genotoxic drugs (94). NRF2 is a transcription factor that
regulates development and drug resistance of human NSCLC
(24). NSCLCs show NRF2 upregulation, and SIRT5 KD
resulted in reduced NRF2 levels, and expression of down-
stream targets of NRF2 (94). These observations highlighted
the potential role of SIRT5 in promoting lung cancer growth
and drug resistance, by promoting the expression of NRF2
and its downstream targets (94). Another study proposed that
SIRT5-mediated SOD1 desuccinylation and activation might
be relevant in lung tumor cell growth (88). SOD1 KD lung
tumor cells expressing succinylation-resistant SOD1 mutant
displayed reduced proliferation (88), potentially indicating
that regulation of SOD1 via succinylation is critical for lung
tumor cell growth. Clearly, further studies are warranted to
explore the possible involvement of SIRT5 in tumorigenesis
and reprograming of cancer cell metabolism.
An Interplay Between Mitochondrial Sirtuins
Contributes to Metabolic Homeostasis
Maintenance of metabolic homeostasis is crucial for
proper cellular function, and it is achieved by tightly regu-
lated interactions among different metabolic pathways under
diverse physiological conditions. Mitochondrial sirtuins are
critical regulators of multiple metabolic processes, and they
influence numerous aspects of metabolic homeostasis in a
carefully orchestrated manner (Fig. 6). For instance, under
chow feeding conditions, SIRT4 represses AASIS by in-
hibiting the activity of GDH (52), which catalyzes the
conversion of glutamate into the Krebs cycle intermediate a-
ketoglutarate (95), thereby promoting cellular glucose me-
tabolism. However, during CR, SIRT4 activity is suppressed,
and thus GDH is released from SIRT4-mediated inhibition
(52, 165). Moreover, it has been reported that acetylation of
GDH also reduces its activity, whereas SIRT3-mediated
deacetylation activates it (91, 137). Therefore, it is possible
that during CR, increased SIRT3 activity induces hepatic
glucose production from amino acids by activating GDH-
mediated conversion of glutamate into a-ketoglutarate (91,
137), which fuels the Krebs cycle. Another example where
coordination between SIRT3 and SIRT4 has been observed is
the regulation of FAO. As noted, during fasting, SIRT3
promotes FAO through LCAD and AMPK (58, 142). Con-
versely, SIRT4 suppresses FAO by negatively regulating the
activities of MCD, PPARa, and AMPK (83, 84). Further,
SIRT4 KD increases the expression of SIRT1, which acti-
vates PPARa and increases FAO gene expression (83, 104).
Collectively, these results suggest that under conditions of
glucose deprivation, crosstalk between SIRT3 and SIRT4
may stimulate utilization of alternative energy sources such
as amino acids and fatty acids.
Recent studies illustrate potential crosstalk between
SIRT3 and SIRT5, both of which activate the enzymes in-
volved in ketogenesis and the urea cycle. Ketone bodies,
an important source of energy for extrahepatic tissues under
fasting conditions, are produced in mitochondria from
acetyl-CoA. SIRT3-mediated activation of AceCS2 results
in enhanced acetyl-CoA production (53, 138). Acetyl-CoA
is then converted into 3-hydroxy-3-methylglutaryl-CoA by
HMGCS2, which is finally converted into ketone bodies.
FIG. 6. Overview of interplay between mitochondrial
sirtuins. Enzymes involved in ketogenesis (blue boxes) and
urea cycle (gray boxes) are activated by both SIRT3 and
SIRT5. While SIRT5 inhibits the enzymatic activities of
glucose metabolism (magenta box), SIRT3 activates them to
suppress metabolic reprogramming and tumorigenesis. SIRT3
also suppresses tumorigenesis by decreasing ROS levels
through activation of antioxidant machinery (green box).
SIRT5 activates SOD1 (orange box) to maintain ROS below
toxic levels to support tumor cell survival. SIRT3 also
shares common target/pathways with SIRT4. SIRT3 pro-
motes FAO by activating LCAD and AMPK (red box),
whereas SIRT4 represses FAO through inhibition of MCD,
PPARa, and AMPK ( pink box). Similarly, SIRT3 activates
GDH (violet box), which is inhibited by SIRT4. To see this
illustration in color, the reader is referred to the web version
of this article at www.liebertpub.com/ars

















































HMGCS2 is activated by both SIRT3-mediated deacetyla-
tion (144) and SIRT5-mediated desuccinylation (127). In
addition, under the conditions of fasting, amino acids are
catabolized as a carbon source for gluconeogenesis. Toxic
ammonia is generated in this process, requiring conversion
into urea for proper disposal via the urea cycle. During CR,
SIRT3 and SIRT5 play pivotal roles in the urea cycle by
activating OTC (54) and CPS1 (34, 102, 156), respectively.
CPS1 catalyzes the initial rate-limiting step in the urea cycle
and converts ammonia into carbamoyl phosphate (171).
OTC is the second enzyme involved in the mitochondrial urea
cycle, and catalyzes the conversion of carbamoyl phosphate
into citrulline (171). Although modulation of enzymatic ac-
tivities in ketogenesis and urea cycle by SIRT3 and SIRT5
highlights their important roles in the adaptive response to
fasting, mechanistic understanding of this coordination is
incomplete.
We have already discussed roles of SIRT3 and SIRT5 in
ROS regulation, generated as a by-product of OXPHOS,
and also in the modulation of activities of enzymes in-
volved in glucose metabolism. While ROS are produced as
a product of normal cellular functioning, increased ROS
levels often result in oxidative stress and adversely affect
genomic stability, promoting tumorigenesis (161). More-
over, increased ROS levels stabilize HIF1a, which pro-
motes a shift toward glycolysis, providing advantages to
rapidly dividing tumor cells (11, 39, 79). As described
earlier, SIRT3 enhances the ability of mitochondria to
detoxify ROS by activating IDH2 (151) and SOD2 (124,
159) and potentially by increasing the expression of anti-
oxidants through an interaction with FoxO3a (153).
Therefore, by reducing the ROS levels, SIRT3 functions as
a tumor suppressor by maintaining genomic stability and
destabilizing HIF1a. As previously noted, elevated ROS
promote carcinogenesis; however, excessive ROS levels
beyond a toxic threshold may overwhelm cellular antiox-
idant capacity and trigger cell cycle arrest and apoptosis
(161). Therefore, reduced SIRT3 expression in cancer cells
is likely to impose increased demand on the antioxidant
machinery to protect cells from the deleterious effects of
elevated ROS levels. Studies from several groups indicate
an important role of SOD1 in tumor initiation and pro-
gression (114). SOD1 is overexpressed in many types of
cancer cells (113, 152), and its activity may be essential for
limiting ROS levels to a level that is consistent with robust
cellular proliferation. In this regard, a recent study by Lin
et al. found that succinylation of SOD1 leads to decreases
in its activity (88). SIRT5 binds to, desuccinylates, and
activates SOD1. Expression of SIRT5 potentiates SOD1-
mediated ROS scavenging (88). These results highlight a
potential role of SIRT5 in the defense mechanisms of
cancer cells against ROS-induced apoptosis, by promoting
SOD1 activity. In this context, Lu et al. showed that
SIRT5 is overexpressed in NSCLC, and SIRT5 KD re-
sults in the repression of NSCLC cells growth (94). In
addition, SIRT5 represses the activities of PDC and SDH
(116), both of which have a critical role in cancer cell
metabolic reprogramming, and PDC activity is suppressed
in many types of tumor cells. This represents an example
of mutual antagonism between SIRT3 and SIRT5, as
SIRT3 increases the activities of PDC (35) and SDHA
(27, 40).
Concluding Remarks
Recent findings in sirtuin biology have highlighted the
importance of mitochondrial sirtuins in regulating multiple
metabolic pathways. Owing to their important roles in
metabolic regulation, mitochondrial sirtuins may represent
attractive candidates for development of therapeutic inter-
ventions against cancer and other diseases. However, many
protein targets are common among mitochondrial sirtuins,
and the degree to which these proteins functionally interact
with each other has yet to be addressed. Additional work is
also required to better understand potential redundancy in
their functions, and the ways they respond to different envi-
ronmental stimuli. Finally, the identification of novel lysine
acyl modifications regulated by mitochondrial sirtuins and
the diverse array of their putative targets suggest that our
understanding of these important regulators is truly still in its
infancy.
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AASIS¼ amino acid stimulated insulin secretion
ACAT1¼ acetyl-CoA acetyltransferase 1
ACC¼ acetyl-CoA carboxylase
AceCS2¼ acetyl-CoA synthetase 2
AHL¼ age-related hearing loss
AMPK¼AMP-activated kinase
ANT2¼ATP/ADP translocase 2
CPS1¼ carbamoyl phosphate synthetase 1
CPT1¼ carnitine palmitoyltransferase 1
CR¼ calorie restriction
CREB2¼ cAMP response element binding protein 2
CSE¼ cigarette smoke extract
ERRE¼ estrogen-related receptor-binding element
ETC¼ electron transport chain




HIF1a¼ hypoxia-inducible factor 1-alpha
HMGCS2¼ 3-hydroxy-3-methylglutaryl CoA synthase 2
HPMECs¼ human pulmonary microvascular endothelial
cells
HSCs¼ hematopoietic stem cells
IDH2¼ isocitrate dehydrogenase 2
IRE¼ iron response element
IRP1¼ iron regulatory protein 1
KD¼ knockdown
KO¼ knockout
LCAD¼ long-chain-specific acyl-CoA dehydrogenase
MCD¼malonyl-CoA decarboxylase
MEFs¼mouse embryonic fibroblasts
mPTP¼mitochondrial permeability transition pore
mtDNA¼mitochondrial DNA
mTORC1¼mechanistic target of rapamycin complex 1
NAD+¼ nicotinamide adenine dinucleotide
NAM¼ nicotinamide
NAMPT¼ nicotinamide phosphoribosyltransferase
NDUFA9¼NADH dehydrogenase (ubiquinone) 1 alpha
subcomplex 9
NSCLC¼ non-small cell lung cancer
OPA1¼ optic atrophy protein 1
OSCC¼ oral squamous cell carcinoma
OTC¼ ornithine transcarbamoylase
PDC¼ pyruvate dehydrogenase complex
PDK¼ pyruvate dehydrogenase kinase
PDP1¼ pyruvate dehydrogenase phosphatase 1
PGC-1a¼ peroxisome proliferator-activated receptor
gamma coactivator 1-alpha
PPARa¼ peroxisome-activated receptor a
PTM¼ post-translational modification
ROS¼ reactive oxygen species
SCD1¼ stearoyl-CoA desaturase 1
SDH¼ succinate dehydrogenase
SDHA¼ succinate dehydrogenase subunit A
Skp2¼ S-phase kinase-associated protein 2
SOD1¼Cu/Zn superoxide dismutase
SOD2¼Mn superoxide dismutase
TFAM¼mitochondrial transcription factor A
TSC2¼ tuberous sclerosis 2
UPRmt¼mitochondrial unfolded protein response
WT¼wild type
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